Titre
Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis.
Type
article
Institution
UNIL/CHUV/Unisanté + institutions partenaires
Périodique
Auteur(s)
Sotgiu, G.
Auteure/Auteur
Centis, R.
Auteure/Auteur
D'Ambrosio, L.
Auteure/Auteur
Alffenaar, J.W.
Auteure/Auteur
Anger, H.A.
Auteure/Auteur
Caminero, J.A.
Auteure/Auteur
Castiglia, P.
Auteure/Auteur
De Lorenzo, S.
Auteure/Auteur
Ferrara, G.
Auteure/Auteur
Koh, W.J.
Auteure/Auteur
Schecter, G.F.
Auteure/Auteur
Shim, T.S.
Auteure/Auteur
Singla, R.
Auteure/Auteur
Skrahina, A.
Auteure/Auteur
Spanevello, A.
Auteure/Auteur
Udwadia, Z.F.
Auteure/Auteur
Villar, M.
Auteure/Auteur
Zampogna, E.
Auteure/Auteur
Zellweger, J.P.
Auteure/Auteur
Zumla, A.
Auteure/Auteur
Migliori, G.B.
Auteure/Auteur
Liens vers les personnes
Liens vers les unités
ISSN
1399-3003
Statut éditorial
Publié
Date de publication
2012
Volume
40
Numéro
6
Première page
1430
Dernière page/numéro d’article
1442
Peer-reviewed
Oui
Langue
anglais
Notes
Publication types: Journal Article
Résumé
Linezolid is used off-label to treat multidrug-resistant tuberculosis (MDR-TB) in absence of systematic evidence. We performed a systematic review and meta-analysis on efficacy, safety and tolerability of linezolid-containing regimes based on individual data analysis. 12 studies (11 countries from three continents) reporting complete information on safety, tolerability, efficacy of linezolid-containing regimes in treating MDR-TB cases were identified based on Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Meta-analysis was performed using the individual data of 121 patients with a definite treatment outcome (cure, completion, death or failure). Most MDR-TB cases achieved sputum smear (86 (92.5%) out of 93) and culture (100 (93.5%) out of 107) conversion after treatment with individualised regimens containing linezolid (median (inter-quartile range) times for smear and culture conversions were 43.5 (21-90) and 61 (29-119) days, respectively) and 99 (81.8%) out of 121 patients were successfully treated. No significant differences were detected in the subgroup efficacy analysis (daily linezolid dosage ≤600 mg versus >600 mg). Adverse events were observed in 63 (58.9%) out of 107 patients, of which 54 (68.4%) out of 79 were major adverse events that included anaemia (38.1%), peripheral neuropathy (47.1%), gastro-intestinal disorders (16.7%), optic neuritis (13.2%) and thrombocytopenia (11.8%). The proportion of adverse events was significantly higher when the linezolid daily dosage exceeded 600 mg. The study results suggest an excellent efficacy but also the necessity of caution in the prescription of linezolid.
PID Serval
serval:BIB_F5F7B9F1FC03
PMID
Open Access
Oui
Date de création
2013-01-03T18:03:01.806Z
Date de création dans IRIS
2025-05-21T05:18:48Z